Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152903 | 1.00 | MAOB (0.69) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL5707175 | 1.00 | MAOB (0.69) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL69522 | 0.87 | ALDH1A1 (0.58) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL10438847 | 0.87 | ALDH1A1 (0.58) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL9639577 | 0.85 | HDAC1 (0.58) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL11061667 | 0.85 | ALDH1A1 (0.56) | MAOBMEN1KMT2AMAPTNPC1 | |
| SCHEMBL15524075 | 0.85 | MAOB (0.52) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL15524074 | 0.85 | MAOB (0.52) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL6821231 | 0.83 | MAOB (0.51) | MAOBHDAC1HDAC8HDAC6MEN1 | |
| SCHEMBL933658 | 0.83 | MAOB (0.51) | MAOBHDAC1HDAC8HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-02-13 | — | — | US | disclosed |
| EP-4211125-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-116234798-A | Sulfamate derivative compounds for the treatment or alleviation of psychotic disorders | 生物药品解决方案有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20220315686-A1 | CURABLE COMPOSITION, CURED SUBSTANCE, OPTICAL MEMBER, AND LENS | FUJIFILM CORPORATION (JP) | 2022-10-06 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| WO-2022054987-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2022-03-17 | — | — | WO | disclosed |
| WO-2021132037-A1 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER AND LENS | 富士フイルム株式会社 | 2021-07-01 | — | — | WO | disclosed |
| CN-106507667-B | Sulfamate derivatives for the prevention or treatment of epilepsy | 比皮艾思药物研发有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3443959-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| WO-2014140353-A1 | METHODS FOR PHOSPHINE OXIDE REDUCTION IN CATALYTIC WITTIG REACTIONS | DUBLIN CITY UNIVERSITY (IE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013187727-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-12-19 | — | — | WO | disclosed |
| EP-1833789-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS BV (NL) | 2011-07-06 | — | — | EP | disclosed |
| US-7732621-B2 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP ASSETS B.V. (NL) | 2010-06-08 | — | — | US | disclosed |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1833789-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSMIP Assets B.V. (NL) | 2007-09-19 | — | — | EP | disclosed |
| US-20060223873-A1 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION | 2006-10-05 | — | — | US | disclosed |
| WO-2006069799-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED INDOLINE-2-CARBOXYLIC ACID | DSM IP ASSETS B.V. (NL) | 2006-07-06 | — | — | WO | disclosed |
| EP-1676838-A1 | Process for the preparation of enantiomerically enriched indoline-2-carboxylic acid | DSM IP Assets B.V. (NL) | 2006-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223873-A1 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | NOS1, NOS2, NOS3 | MAOB 1078/4885HDAC1 1372/4885HDAC8 1883/4885 |
| US-20220218702-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER | SLC6A4, SLC6A3, SLC6A2 | MAOB 245/4885HDAC1 83/4885HDAC8 154/4885 |
| US-20090043112-A1 | Process for the Preparation of Enantiomerically Enriched Indoline-2-Carboxylic Acid | IDO2, IDO1, KYNU | MAOB 39/4885HDAC1 2697/4885HDAC8 2943/4885 |
| US-11896593-B2 | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder | SLC6A4, SLC6A3, SLC6A2 | MAOB 245/4885HDAC1 83/4885HDAC8 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.